HbA1c diabetes cut-off values are central to diagnosing and managing diabetes in the UK. HbA1c — or glycated haemoglobin — measures average blood glucose over two to three months, giving clinicians a reliable indicator of longer-term glucose control. In the UK, the NHS and NICE recognise 48 mmol/mol (6.5%) as the diagnostic threshold for type 2 diabetes, with 42–47 mmol/mol indicating prediabetes. Understanding these thresholds, what can affect their accuracy, and what happens after an abnormal result is essential for anyone navigating a diabetes diagnosis or monitoring their risk.
Summary: The HbA1c diabetes cut-off in the UK is 48 mmol/mol (6.5%), with 42–47 mmol/mol indicating prediabetes and below 42 mmol/mol considered normal, as defined by NICE and WHO guidance.
- HbA1c measures average blood glucose over the preceding 2–3 months by quantifying glycated haemoglobin in red blood cells.
- In the UK, HbA1c is reported in mmol/mol (IFCC standard); 48 mmol/mol or above on two separate tests confirms type 2 diabetes in asymptomatic individuals.
- A result of 42–47 mmol/mol indicates prediabetes (non-diabetic hyperglycaemia); referral to the NHS Diabetes Prevention Programme is recommended.
- HbA1c should not be used for diagnosis in children, pregnant women, those with suspected type 1 diabetes, or individuals with haemoglobin variants or haemolytic conditions.
- NICE NG28 targets for type 2 diabetes management are 48 mmol/mol for lifestyle or single non-hypoglycaemic drug therapy, and 53 mmol/mol where hypoglycaemia risk exists.
- Conditions such as iron deficiency anaemia, haemolytic anaemia, and chronic kidney disease can falsely alter HbA1c results, requiring alternative diagnostic tests.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is HbA1c and How Is It Measured?
HbA1c is measured in mmol/mol in the UK; a result of 48 mmol/mol or above on a standardised laboratory test is diagnostic of type 2 diabetes, while 42–47 mmol/mol indicates prediabetes.
HbA1c — formally known as glycated haemoglobin — is a blood marker that reflects average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin within red blood cells, forming HbA1c. Because red blood cells have a lifespan of approximately 120 days, the test provides a reliable window into longer-term glucose control, rather than a single-point snapshot.
In the UK, HbA1c is measured in millimoles per mole (mmol/mol), following the IFCC (International Federation of Clinical Chemistry) standardisation adopted by the NHS. Some reports also display the older percentage (%) equivalent alongside the mmol/mol value for ease of interpretation, but IFCC mmol/mol is the current UK standard. The test must be performed using an IFCC-standardised, quality-assured laboratory method; point-of-care devices should not be used for diagnostic purposes due to concerns about accuracy and standardisation.
The HbA1c diabetes cut-off recognised by NICE and the WHO is:
-
Below 42 mmol/mol (6.0%) — considered normal
-
42–47 mmol/mol (6.0–6.4%) — indicates prediabetes (non-diabetic hyperglycaemia)
-
48 mmol/mol (6.5%) or above — diagnostic of type 2 diabetes (when confirmed on a second test in asymptomatic individuals)
For individuals with classic symptoms of diabetes (such as polyuria, polydipsia, or unexplained weight loss), a single HbA1c result of 48 mmol/mol or above is sufficient for diagnosis.
Important diagnostic limitations — HbA1c should not be used for diagnosis in:
-
Children and young people
-
Pregnant women or those being assessed for gestational diabetes
-
Individuals with suspected type 1 diabetes
-
People with acute illness or acute hyperglycaemia
-
Individuals with conditions affecting red blood cell survival or haemoglobin variants (see below)
In these circumstances, fasting plasma glucose or an oral glucose tolerance test (OGTT) should be used instead, in line with NICE NG28 and WHO guidance. Understanding these thresholds and their limitations is essential for both patients and clinicians in interpreting results accurately and planning appropriate next steps.
Prediabetes and Borderline HbA1c Ranges Explained
An HbA1c of 42–47 mmol/mol indicates prediabetes; lifestyle intervention through the NHS Diabetes Prevention Programme can reduce progression to type 2 diabetes.
Prediabetes — also referred to as non-diabetic hyperglycaemia (NDH) by NHS England — describes a state in which blood glucose levels are elevated above normal but have not yet reached the threshold for a diabetes diagnosis. An HbA1c result in the range of 42–47 mmol/mol places an individual in this category. Millions of adults in the UK are currently living with prediabetes, many of whom are unaware of their status.
This borderline range is clinically significant because it represents a critical window for intervention. Research consistently shows that lifestyle modifications — including dietary changes, increased physical activity, and weight management — can substantially reduce the risk of progression to type 2 diabetes. The NHS Diabetes Prevention Programme (NHS DPP) is specifically designed for individuals with HbA1c results in this range (42–47 mmol/mol) or a fasting plasma glucose of 5.5–6.9 mmol/L, offering structured, evidence-based support. Eligibility and referral pathways may vary by local area.
It is important to note that prediabetes does not inevitably progress to type 2 diabetes. With appropriate lifestyle changes, some individuals return to a normal HbA1c range. However, without intervention, the risk of developing type 2 diabetes is considerably elevated over subsequent years. There is also evidence of increased cardiovascular risk associated with non-diabetic hyperglycaemia, making early identification and management important.
Patients with a borderline result should treat it as a meaningful prompt to:
-
Review dietary habits, particularly refined carbohydrate and sugar intake
-
Increase physical activity to at least 150 minutes of moderate exercise per week
-
Attend follow-up monitoring, typically every 6–12 months depending on individual risk and local pathways, as recommended by their GP
Patients are encouraged to contact their GP sooner if they develop symptoms such as increased thirst, frequent urination, unexplained fatigue, or blurred vision.
Factors That Can Affect HbA1c Accuracy
Conditions including haemolytic anaemia, iron deficiency, haemoglobin variants, and chronic kidney disease can falsely alter HbA1c results, making fasting plasma glucose or OGTT preferable for diagnosis in these cases.
Whilst HbA1c is a robust and widely validated diagnostic tool, several clinical and physiological factors can affect its accuracy, potentially leading to falsely elevated or falsely low results. Clinicians and patients should be aware of these limitations, particularly when results appear inconsistent with other clinical findings.
Conditions that may falsely lower HbA1c include:
-
Haemolytic anaemia (increased red cell turnover reduces HbA1c accumulation)
-
Recent blood transfusion
-
Haemoglobin variants such as sickle cell trait or haemoglobin C disease
-
Pregnancy (particularly the second and third trimesters, due to altered red cell dynamics)
Conditions that may falsely elevate HbA1c include:
-
Iron deficiency anaemia (before treatment)
-
Vitamin B12 or folate deficiency
-
Splenectomy (prolonged red cell survival)
-
Chronic kidney disease (CKD) — the effect is variable and assay-dependent; CKD can cause both interference via carbamylation of haemoglobin and altered erythrocyte lifespan, so results should be interpreted with caution
In any of these circumstances, HbA1c should not be used for diagnosis. NICE NG28 recommends using fasting plasma glucose or an oral glucose tolerance test (OGTT) when HbA1c is considered unreliable. For ongoing monitoring in people already diagnosed, capillary blood glucose self-monitoring or continuous glucose monitoring (CGM) may be considered as clinically appropriate.
It is also worth noting that ethnicity may influence HbA1c levels independently of glucose control; UK-based evidence suggests that individuals of South Asian, African, or Afro-Caribbean descent may have slightly higher HbA1c values at equivalent glucose levels, though this is not yet fully reflected in adjusted diagnostic thresholds in UK practice.
If there is any clinical doubt about the reliability of an HbA1c result, patients should discuss this with their GP or diabetes care team, who can arrange supplementary testing as appropriate.
| Category | HbA1c (mmol/mol) | HbA1c (%) | Interpretation | Recommended Action (NHS/NICE) |
|---|---|---|---|---|
| Normal | Below 42 mmol/mol | Below 6.0% | Normal glucose regulation | Routine review; maintain healthy lifestyle |
| Prediabetes (NDH) | 42–47 mmol/mol | 6.0–6.4% | Non-diabetic hyperglycaemia; elevated risk of type 2 diabetes | Refer to NHS Diabetes Prevention Programme; repeat HbA1c in 6–12 months |
| Diabetes (asymptomatic) | 48 mmol/mol or above | 6.5% or above | Diagnostic of type 2 diabetes if confirmed on second test | Confirm with second laboratory HbA1c on separate day (NICE NG28) |
| Diabetes (symptomatic) | 48 mmol/mol or above | 6.5% or above | Single result sufficient for diagnosis with classic symptoms | Immediate clinical assessment; no repeat test required |
| Type 2 diabetes — treatment target (low hypoglycaemia risk) | 48 mmol/mol | 6.5% | NICE NG28 target: lifestyle/diet alone or single non-hypoglycaemic drug | Monitor every 3–6 months when adjusting treatment; every 6 months when stable |
| Type 2 diabetes — treatment target (hypoglycaemia risk) | 53 mmol/mol | 7.0% | NICE NG28 target: sulphonylureas, insulin, or other hypoglycaemia-risk drugs | Individualise target; consider less stringent goals in older or frail patients |
| HbA1c unreliable — do not use for diagnosis | N/A | N/A | Haemoglobin variants, haemolytic anaemia, pregnancy, CKD, recent transfusion | Use fasting plasma glucose or OGTT instead (NICE NG28) |
What Happens After an Abnormal HbA1c Result on the NHS
Asymptomatic individuals with an HbA1c of 48 mmol/mol or above require a confirmatory second test before a type 2 diabetes diagnosis is made; symptoms of type 1 diabetes or DKA require urgent same-day assessment.
Receiving an abnormal HbA1c result can feel unsettling, but the NHS has clear, structured pathways to support patients at every stage. The response depends on whether the result falls in the prediabetic or diabetic range, and whether the individual has symptoms.
For asymptomatic individuals with an HbA1c of 48 mmol/mol or above, NICE NG28 recommends that the result be confirmed with a second laboratory HbA1c (or plasma glucose) on a separate day, as soon as practicable. A confirmed result on two separate occasions is required before a formal diagnosis of type 2 diabetes is made. This safeguard helps avoid misdiagnosis due to laboratory error or transient hyperglycaemia caused by acute illness or stress.
Urgent same-day assessment is required if there are symptoms or signs suggestive of type 1 diabetes or diabetic ketoacidosis (DKA), including rapid-onset polyuria, polydipsia, significant unintentional weight loss, nausea or vomiting, abdominal pain, drowsiness, or deep laboured breathing. These features require immediate medical attention and should not await a repeat HbA1c.
Once a diagnosis of type 2 diabetes is confirmed, the GP will typically:
-
Arrange a structured diabetes education programme, such as the NHS-funded DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) course
-
Conduct a full diabetes review, including blood pressure, cholesterol, kidney function (eGFR and urine ACR), and foot examination
-
Refer to the NHS Diabetic Eye Screening Programme, which should be initiated shortly after diagnosis
-
Discuss treatment options, which may initially focus on lifestyle modification before considering pharmacological therapy such as metformin
-
Register the patient on the GP diabetes register to ensure ongoing review and QOF (Quality and Outcomes Framework) monitoring
For those in the prediabetic range (42–47 mmol/mol), a GP will typically refer to the NHS Diabetes Prevention Programme and arrange repeat HbA1c testing in 6–12 months, tailored to individual risk. Patients are encouraged to contact their GP sooner if they develop symptoms of hyperglycaemia, as these may indicate progression to diabetes.
Managing Your HbA1c: NICE Guidelines and Next Steps
NICE NG28 recommends an HbA1c target of 48 mmol/mol for those on lifestyle or single non-hypoglycaemic therapy, with monitoring every 3–6 months when adjusting treatment and every 6 months once stable.
For individuals already diagnosed with type 2 diabetes, ongoing HbA1c monitoring is central to managing the condition and reducing the risk of long-term complications, including cardiovascular disease, nephropathy, retinopathy, and neuropathy. NICE guideline NG28 provides clear targets for HbA1c management in type 2 diabetes.
NICE-recommended HbA1c targets for type 2 diabetes:
-
48 mmol/mol (6.5%) — target for individuals managed by lifestyle and diet alone, or with a single non-hypoglycaemia-inducing drug
-
53 mmol/mol (7.0%) — target for individuals on drugs that carry a risk of hypoglycaemia (e.g., sulphonylureas or insulin)
-
Targets should be individualised, taking into account age, frailty, comorbidities, treatment burden, and patient preference; less stringent targets may be appropriate for older or frail patients
Achieving and maintaining HbA1c within the target range significantly reduces the risk of microvascular and macrovascular complications. However, overly aggressive glucose lowering — particularly in older or frail patients — can increase the risk of hypoglycaemia, which carries its own serious risks including falls, cardiac events, and cognitive impairment.
HbA1c monitoring frequency (NICE NG28):
-
Every 3–6 months when treatment is being initiated or adjusted
-
Every 6 months once the individual is stable on treatment
People taking insulin or sulphonylureas should also self-monitor blood glucose as directed by their diabetes care team, to help detect and manage hypoglycaemia.
From a practical standpoint, patients can support their HbA1c management through:
-
Dietary modification: reducing refined carbohydrates, sugary drinks, and processed foods; following a Mediterranean-style or low-glycaemic-index diet
-
Regular physical activity: both aerobic exercise and resistance training have been shown to lower HbA1c independently of weight loss
-
Medication adherence: taking prescribed medications consistently and reporting any side effects to the GP or diabetes nurse
-
Reporting suspected side effects: in addition to informing your GP or diabetes nurse, suspected adverse reactions to any medicine can be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
Patients should contact their GP or diabetes care team promptly if their HbA1c rises significantly between reviews, if they experience symptoms of hypoglycaemia or hyperglycaemia, or if they have concerns about their medication. Self-management is most effective when supported by a collaborative relationship with the wider NHS diabetes team.
Frequently Asked Questions
What is the HbA1c cut-off for diagnosing type 2 diabetes in the UK?
In the UK, an HbA1c of 48 mmol/mol (6.5%) or above is the diagnostic cut-off for type 2 diabetes, in line with NICE and WHO guidance. Asymptomatic individuals require a confirmatory second test on a separate day before a formal diagnosis is made.
What does an HbA1c result of 42–47 mmol/mol mean?
An HbA1c of 42–47 mmol/mol indicates prediabetes, also called non-diabetic hyperglycaemia. This is a reversible stage where lifestyle changes — such as improved diet and increased physical activity — can significantly reduce the risk of progressing to type 2 diabetes, and referral to the NHS Diabetes Prevention Programme is recommended.
Can HbA1c results be inaccurate?
Yes, certain conditions can affect HbA1c accuracy, including haemolytic anaemia, iron deficiency anaemia, haemoglobin variants such as sickle cell trait, and chronic kidney disease. In these cases, NICE recommends using fasting plasma glucose or an oral glucose tolerance test (OGTT) for diagnosis instead.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
